|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Semi-quantitative Real-Time PCR (RT-PCR) showed that both freshly sorted CD44(+) and CD44(+) cells derived from CD44(+)-initiated tumors expressed the pluripotency genes OCT4/POU5F1, NANOG, SOX2.
|
21124918 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Ubiquitination-defective mutant of OCT4(K284R) overexpressed cells drastically generated tumor burdens in mice.
|
29511337 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All cell lines were positive for Oct3/4 and nucleostemin; NSTS-11 cells were also able to form xenograft tumors in mice.
|
22156015 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we establish a sustainable primary culture of Oct3/4(+)/Nanog(+) lung CSCs fed with CD90(+) cancer-associated fibroblasts (CAFs) to further advance our knowledge of preserving stem cells in the tumour microenvironment.
|
24668028 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Considering the link between EMT and cancer stem cells, we show that PARP3 promotes stem-like cell properties in mammary epithelial and breast cancer cells by inducing the expression of the stem cell markers SOX2 and OCT4, by increasing the proportion of tumor initiating CD44high/CD24low population and the formation of tumor spheroid bodies, and by promoting stem cell self-renewal.
|
27579892 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data revealed a significant coupregulation of SOX2OT along with SOX2 and OCT4 in tumor samples, compared to the non-tumor tissues obtained from the margin of same tumors.
|
24105929 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, CD133- and/or Oct3/4-positive cholangiocarcinoma patients had significant associations with tumor histology types, tumor stage, and poor prognoses.
|
23917144 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Meanwhile, FoxM1 linked closely with the expression levels of stem cell markers including Nanog, Sox2, and OCT4 in tumor samples, and also promoted the expression of these stemness-related genes <i>in vitro</i>.
|
30416986 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cells treated with 5-FU also exhibited tumorigenic potential, based on tumor formation assays in nude mice, and Oct3/4-positive cell aggregates were identified in the resulting tumors.
|
23216104 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Re-activation of these pluripotent transcription factors (Nanog, Oct4 and/or Sox2) in association with distinct tumorigenic properties could be found in clones isolated from gynecological tumors using various approaches.
|
22806899 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, positive/high Oct-4 was associated with cancer stage III/IV (fixed effects: OR = 1.53, 95% CI = 1.12-2.10), primary tumor (T3-4) (random effects: OR = 1.93, 95% CI = 0.99-3.77), and cancer grade of differentiation (intermediate-poor) (random effects: OR = 3.45, 95% CI = 1.5-7.61).
|
26575328 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Altogether, our data highlights an unprecedented role for OCT4 as central regulator of mitotic fidelity and RB tumor suppressor pathway activity.
|
28319064 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We propose that Oct3/4, Sox2 and Nanog are associated with tumor hypoxia characterized in oral SCC and that these factors may also contribute to the undifferentiated potency observed in oral SCC clinically.
|
28314267 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These more invasive cells have been previously characterized as tumor initiating cells (TICs) that have a stem-like genomic signature and express a number of stem cell genes including Oct3/4 and Nanog and are more tumorigenic compared to their 'non-invasive' counterpart.
|
20929579 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of tumor-bearing mice with genotoxic chemotherapy not only prolonged survival and reduced tumor size but also selectively eliminated the OCT4-positive cancer stem cells.
|
29141221 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent advances related to cytogenetic and molecular features have established the role of immunohistochemistry of c-kit, OCT-3/4 and determination of gain of chromosome 12 in the daily workup of premalignant lesions and invasive tumors.
|
17169757 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oct4 mediates tumor initiating properties in oral squamous cell carcinomas through the regulation of epithelial-mesenchymal transition.
|
24475251 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, DOX induced cell senescence and reduced tumor sphere formation and the proportion of NANOG- and OCT4-positive cells after 7 days.
|
28612256 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Between Oct 4, 2012, and July 11, 2014, we screened 741 patients with any tumour type.
|
26342236 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Octamer‑binding transcription factor 4 (Oct4) has been identified as a novel transcription factor associated with tumorigenesis, acquisition and maintenance of cancer stem cell characteristics and poor prognosis in tumors.
|
29901157 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Grp78 knockdown dramatically restrained tumor growth along with the inhibition of stem cell regulatory proteins Oct-4 and Slug.
|
24201869 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The promoter regions of ABCB1, ABCG2 and ABCC1 genes contain binding sites for the Oct-4 transcripton factor, which is also considered a marker of tumor stem cells.
|
19969351 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia upregulates the core pluripotency factors NANOG, SOX2, and OCT4, associated with tumor aggressiveness and resistance to conventional anticancer treatments.
|
28093523 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, major progress has been made in identifying gene-products related to germ cell tumor development (testis-specific protein-Y encoded and octamer binding transcription factor 3/4) and in recognizing early changes of germ cells (maturation delay, preneoplastic lesions, and in situ neoplasia).
|
16735607 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on the results of present study and published reports showing the presence of pluripotent markers (OCT-4, NANOG and SOX2) in human myometrial side population and expression of particularly OCT-4A in human leiomyomas, we speculate that these nuclear OCT-4 positive stem cells located in the perimetrium are the possible tumor initiating cells leading to the development of leiomyomas rather than the mesenchymal cells which express cytoplasmic OCT-4B.
|
28438190 |
2017 |